GlassScriptPhysician profile
Junnesh Moushi
NPI 1083395966
$1,511.01
in general payments reported to CMS, 2019-2025
19 companies · $579 in 2025
The $579 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $308 · 2024: $624 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $366.43 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $256.10 | 2023-2025 | |
| Abbvie INC. | $200.87 | 2023-2025 | |
| Glaxosmithkline, LLC. | $143.54 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.99 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $79.48 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $55.21 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $49.32 | 2025 | General - Therapies |
| Inspire Medical Systems, INC. | $31.06 | 2025 | Inspire |
| Indivior INC. | $30.23 | 2023 | Sublocade |
| Edwards Lifesciences Corporation | $23.55 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $21.23 | 2025 | Proclaim |
| Exact Sciences Corporation | $20.42 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $19.75 | 2024 | Repatha, Otezla |
| Biogen, INC. | $19.60 | 2024 | Spinraza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.42 | 2024 | Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.51 | 2025 | Lifevest |
| Medtronic, INC. | $16.18 | 2025 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $15.12 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junnesh Moushi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.